U.S. Drug of Abuse (DoA) Testing Market Overview

The U.S. Drug of Abuse (DoA) testing market size was estimated at approximately USD 5.6 billion in 2025 and is expected to reach around USD 6.3 billion in 2026, rising to nearly USD 10.7 billion by 2035, growing at an estimated 6.4% CAGR during 2026 to 2035.

Research Highlights

Urine testing held 61.5% market share in 2025 driven by established protocols.
Consumables captured 46.7% share in 2025 due to recurring demand.
Diagnostic laboratories accounted for 41.6% revenue share in 2025 owing to testing volume.
Saliva testing is projected at 9.1% CAGR during 2026 to 2035, driven by rapid detection.
Northeastern U.S. represented 28.7% market share in 2025 supported by healthcare infrastructure.

Market growth is fueled by the growing prevalence of substance abuse, an increase in the need for workplace safety, and a growing number of forensic and clinical toxicology testing applications, as well as the adoption of rapid testing and laboratory automation. The demand for reliable drug testing and the continuous investment in substance abuse programs by entities such as the Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for Disease Control and Prevention (CDC), and the National Institute on Drug Abuse (NIDA) will fuel market growth in California, Texas, New York, Florida, and the rest of the US.

U.S. Drug of Abuse (DoA) Testing Market Dynamics

Market Trends

The US Drug of Abuse (DoA) testing market is characterized by an increase in testing accuracy, rapid screening, and digital laboratory solutions. One of the major trends influencing the market is the growing need for point of care testing devices that promote a shift in attitude towards faster results and overall convenience. The Substance Abuse and Mental Health Services Administration (SAMHSA) has been supportive in the adoption of evidence-based programs for substance abuse prevention and treatment. Another noteworthy trend is the rising adoption of automated laboratory systems and new immunoassays and confirmatory testing using chromatography technology, which is led by the innovation in testing technologies and an increase in the need for reliable detection.

Growth Drivers

The growth of the market is primarily driven by the rising cases of substance abuse and opioid epidemic which in turn propel demand from healthcare, workplace, and government sectors. An increase in the number of employee drug testing, forensic testing, and clinical toxicology procedures is some of the major factors driving the market during the forecast period. The CDC has been instrumental in tracking drug overdoses and abuse while promoting prevention and control measures. Workplace safety regulations and the adoption of drug testing programs in the workplace have become a great driver for the market.

Market Restraints / Challenges

Even though the market is projected to witness strong growth over the forecasted period, several factors are likely to restrain the market from registering higher growth rates. In the current scenario, there are several ethical and legal concerns regarding privacy and personal information. Thus, a number of employers are hesitant to adopt drug testing programs due to the fear of potential legal issues. Moreover, false positive results, challenges with detection accuracy, and the need for advanced confirmatory tests present major challenges to manufacturers and lab facilities.

Market Opportunities

The market has witnessed a major shift towards advanced drug testing technologies and rapid diagnostic results. Thus, firms offering innovative yet cost-effective testing technologies and products stand to benefit greatly from the growing demand for advanced and accurate screening solutions from healthcare, employers, forensic labs, and federal government agencies. Another opportunity for firms is the development of digital testing solutions and home screening devices where the adoption of digital laboratory systems and information management is set to create new opportunities for providers while also helping establish long-term partnerships.

U.S. Drug of Abuse (DoA) Testing Market Report Coverage

Report Metric	Details
Historical Period	2020 - 2024
Base Year Considered	2025
Forecast Period	2026 - 2035
Market Size in 2025	USD 5.6 Billion
Revenue Forecast in 2035	USD 10.7 Billion
Growth Rate	6.4%
Segments Covered in the Report	Product Type, Sample Type, Application, End Use
Report Scope	Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report	Northeastern U.S., Southern U.S., Western U.S., Other U.S. Regions
Key Companies	Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trividia Health Inc.
Customization	Available upon request

U.S. Drug of Abuse (DoA) Testing Market Segmentation

By Product Type

The consumables segment dominated the market with a volume share of around 46.7% in 2025, supported by an increased need for testing kits, reagents, strips, and lab consumables for workplace, clinical, and forensic drug testing applications.

Rapid testing devices have been growing at the fastest rate, registering a CAGR of 8.2% between 2026 and 2035, and are projected to be among the most adopted products during the forecast period. Rapid testing devices are witnessing rising demand in clinical, workplace, and forensic drug-testing applications due to the need for point-of-care and quick-screening methods.

By Sample Type

Urine samples dominated the market, registering a volume share of 61.5% in 2025, primarily due to its established acceptance, standardized protocols, and affordability. Additionally, the adoption of urine drug-testing methods is growing due to their widespread usage in workplace and clinical drug-testing programs.

The saliva segment is expected to register the fastest growth at a CAGR of 9.1% during the forecast period. Saliva-based drug tests are witnessing rising demand in the U.S. due to their non-invasive collection process, instant results, and increased adoption in roadside and workplace drug-testing programs.

By Application

The workplace segment dominated the market with a revenue share of 38.9% in 2025, supported by the rising emphasis on employee safety and the need for ensuring productivity and compliance in various industries. The transportation, healthcare, manufacturing, and construction sectors are adopting workplace drug-testing programs to promote a safe working environment and reduce accidents.

Clinical drug testing is projected to register the fastest growth at a CAGR of 7.8% to reach a revenue share of 30.7% by 2035 due to an upsurge in demand due to the rising prevalence of substance abuse coupled with the need for opioid monitoring.

By End Use

The diagnostic laboratories segment dominated the market, registering a share of 41.6% in 2025, due to the high adoption of rapid drug-testing devices and other sophisticated analytical products. Further, diagnostic laboratory networks are projecting to expand at a healthy pace due to the increasing need for high-throughput laboratories and automation.

The government agencies and forensic laboratories segment is expected to grow at a CAGR of 7.3% during the forecast period. Forensic laboratories are focused on adopting state-of-the-art analytical devices for accurate and reliable results. Moreover, substance abuse monitoring and criminal justice programs promote the adoption of drug-testing products and services among forensic laboratories and government agencies.

Regional Insights

Northeastern U.S.

Northeastern U.S. accounted for 28.7% of the U.S. Drug of Abuse (DoA) Testing Market in 2025, fueled by the presence of an extensive healthcare network, leading diagnostic labs, and the growing need for workplace and clinical drug tests in New York, Massachusetts, Pennsylvania, and New Jersey. There is also a surge in the adoption of laboratory automation and other technologies enabled by the robust healthcare ecosystem. Additionally, the Substance Abuse and Mental Health Services Administration’s (SAMHSA) initiatives to promote screening programs will play a critical role in fostering the market growth in the region.

Southern U.S.

Southern U.S. comprised 26.4% of the market in 2025. The region is projected to witness consistent growth in 2025, primarily due to the rising healthcare expenditures and the need for drug-of-abuse testing across Texas, Florida, Georgia, and North Carolina. The Southern U.S. is also witnessing increased investments in developing clinical diagnostic testing services and a rising number of forensic labs. As a result, there has been a surge in the number of diagnostic tests being conducted in the region for detecting substances of abuse in the workplace and other settings. This trend is further complemented by the Centers for Disease Control and Prevention’s (CDC) initiatives to improve nationwide monitoring of the prescription drug and illicit drug overdose epidemic and encourage states to adopt comprehensive prescription monitoring programs.

Western U.S.

Western U.S. made up 21.3% of the market in 2025. The presence of advanced healthcare infrastructure and a large number of research facilities in the region will play a vital role in fueling the demand for DoA testing services. Moreover, the adoption of digital healthcare technologies is also on the rise in the Western U.S., which will further drive the market growth over the forecast period. States such as California, Washington, Arizona, Colorado, and others are witnessing a significant surge in the need for diagnostic testing services in clinical and workplace settings.

The remaining 23.6% will be attributed to the Midwestern U.S., Mountain States, and others during the forecast period due to an increase in the number of healthcare facilities and government initiatives to promote workplace drug testing and monitor substances of abuse.

Competitive Landscape / Company Insights

The market is highly competitive, and many global and regional players are working toward diagnostic innovation, testing precision, automation, and the expansion of laboratory service offerings. Moreover, industry participants are investing heavily in the R&D of advanced immunoassays, chromatography-based methods, digital laboratory discovery, and extended panel implementation. The market development is promoted by several national organizations, including the Substance Abuse and Mental Health Services Administration (SAMHSA), the CDC, and NIDA.

Mini Profiles

Abbott Laboratories focuses on diagnostic testing solutions, toxicology screening platforms, and laboratory technologies, supported by global healthcare expertise and extensive diagnostic capabilities.

Becton Dickinson and Company develops diagnostic products, specimen collection solutions, and healthcare technologies, supported by strong clinical partnerships and advanced laboratory infrastructure.

Bio-Rad Laboratories, Inc. provides diagnostic testing systems and quality control solutions, supported by research capabilities, laboratory expertise, and global healthcare distribution.

Danaher Corporation operates through advanced diagnostic businesses, focusing on laboratory automation, analytical technologies, and integrated testing solutions for healthcare applications.

F. Hoffmann-La Roche Ltd. develops diagnostic platforms and laboratory testing technologies, supported by innovation, global healthcare networks, and advanced molecular diagnostic capabilities.

Key Players

Abbott Laboratories
Becton Dickinson and Company
Bio-Rad Laboratories, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Laboratory Corporation of America Holdings (Labcorp)
Quest Diagnostics Incorporated
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Trividia Health Inc.

Recent Developments

In January 2026, Quest Diagnostics Incorporated expanded its diagnostic testing capabilities through continued investments in laboratory technology and digital healthcare solutions. The development supports increasing demand for efficient substance screening and clinical diagnostic services.

In March 2026, Thermo Fisher Scientific Inc. introduced enhanced analytical testing solutions supporting toxicology and laboratory research applications. The development strengthens its position in advanced diagnostic technologies and high accuracy testing solutions.

In February 2025, Laboratory Corporation of America Holdings (Labcorp) expanded its diagnostic service capabilities through investments in laboratory automation and healthcare testing infrastructure. The initiative supports growing demand for specialised testing services.

In April 2025, Siemens Healthineers AG strengthened its diagnostic technology portfolio through advancements in laboratory automation and digital healthcare solutions. The development supports improved efficiency and accuracy across clinical testing environments.

In May 2025, Abbott Laboratories expanded its diagnostic technology offerings through continued innovation in rapid testing and healthcare screening solutions. The development supports increasing demand for accessible and reliable testing methods.

U.S. Drug of Abuse (DoA) Testing Market Coverage

Product Type Insight and Forecast 2026 - 2035

Immunoassay Analysers
Chromatography Instruments
Rapid Testing Devices
Consumables

Sample Type Insight and Forecast 2026 - 2035

Urine
Saliva
Hair
Blood
Other Biological Samples

Application Insight and Forecast 2026 - 2035

Workplace Testing
Clinical Testing
Forensic Testing
Criminal Justice Testing

End Use Insight and Forecast 2026 - 2035

Hospitals and Healthcare Providers
Diagnostic Laboratories
Workplaces
Forensic Laboratories
Government Agencies

U.S. Drug of Abuse (DoA) Testing Market by Region

A PHP Error was encountered

Severity: Warning

Message: Undefined variable $market_coverage_region

Filename: Frontend/product_page_test.php

Line Number: 438

Backtrace:

File: /home/vynzrese/public_html/application/views/Frontend/product_page_test.php
Line: 438
Function: _error_handler

File: /home/vynzrese/public_html/application/views/Frontend/Layout/product_layout.php
Line: 8
Function: view

File: /home/vynzrese/public_html/application/controllers/ProductPage.php
Line: 86
Function: view

File: /home/vynzrese/public_html/index.php
Line: 300
Function: require_once

Table of Contents for U.S. Drug of Abuse (DoA) Testing Market Report

1. Research Overview

1.1. The Report Offers
1.2. Market Coverage
1.2.1. By Product Type
1.2.2. By Sample Type
1.2.3. By Application
1.2.4. By End Use
1.3. Research Phases
1.4. Limitations
1.5. Market Methodology
1.5.1. Data Sources
1.5.1.1. Primary Research
1.5.1.2. Secondary Research
1.5.2. Methodology
1.5.2.1. Data Exploration
1.5.2.2. Forecast Parameters
1.5.2.3. Data Validation
1.5.2.4. Assumptions
1.5.3. Study Period & Data Reporting Unit

2. Executive Summary

3. Industry Overview

3.1. Industry Dynamics
   3.1.1. Market Growth Drivers
   3.1.2. Market Restraints
   3.1.3. Key Market Trends
   3.1.4. Major Opportunities
3.2. Industry Ecosystem
   3.2.1. Porter’s Five Forces Analysis
   3.2.2. Recent Development Analysis
   3.2.3. Value Chain Analysis
3.3. Competitive Insight
   3.3.1. Competitive Position of Industry Players
   3.3.2. Market Attractive Analysis
   3.3.3. Market Share Analysis

4. U.S. Market Estimate and Forecast

4.1. U.S. Market Overview
4.2. U.S. Market Estimate and Forecast to 2035

5. Market Segmentation Estimate and Forecast

5.1. By Product Type
   5.1.1. Immunoassay Analysers
   5.1.1.1. Market Definition
   5.1.1.2. Market Estimation and Forecast to 2035
   5.1.2. Chromatography Instruments
   5.1.2.1. Market Definition
   5.1.2.2. Market Estimation and Forecast to 2035
   5.1.3. Rapid Testing Devices
   5.1.3.1. Market Definition
   5.1.3.2. Market Estimation and Forecast to 2035
   5.1.4. Consumables
   5.1.4.1. Market Definition
   5.1.4.2. Market Estimation and Forecast to 2035

5.2. By Sample Type
   5.2.1. Urine
   5.2.1.1. Market Definition
   5.2.1.2. Market Estimation and Forecast to 2035
   5.2.2. Saliva
   5.2.2.1. Market Definition
   5.2.2.2. Market Estimation and Forecast to 2035
   5.2.3. Hair
   5.2.3.1. Market Definition
   5.2.3.2. Market Estimation and Forecast to 2035
   5.2.4. Blood
   5.2.4.1. Market Definition
   5.2.4.2. Market Estimation and Forecast to 2035
   5.2.5. Other Biological Samples
   5.2.5.1. Market Definition
   5.2.5.2. Market Estimation and Forecast to 2035

5.3. By Application
   5.3.1. Workplace Testing
   5.3.1.1. Market Definition
   5.3.1.2. Market Estimation and Forecast to 2035
   5.3.2. Clinical Testing
   5.3.2.1. Market Definition
   5.3.2.2. Market Estimation and Forecast to 2035
   5.3.3. Forensic Testing
   5.3.3.1. Market Definition
   5.3.3.2. Market Estimation and Forecast to 2035
   5.3.4. Criminal Justice Testing
   5.3.4.1. Market Definition
   5.3.4.2. Market Estimation and Forecast to 2035

5.4. By End Use
   5.4.1. Hospitals and Healthcare Providers
   5.4.1.1. Market Definition
   5.4.1.2. Market Estimation and Forecast to 2035
   5.4.2. Diagnostic Laboratories
   5.4.2.1. Market Definition
   5.4.2.2. Market Estimation and Forecast to 2035
   5.4.3. Workplaces
   5.4.3.1. Market Definition
   5.4.3.2. Market Estimation and Forecast to 2035
   5.4.4. Forensic Laboratories
   5.4.4.1. Market Definition
   5.4.4.2. Market Estimation and Forecast to 2035
   5.4.5. Government Agencies
   5.4.5.1. Market Definition
   5.4.5.2. Market Estimation and Forecast to 2035

5. Company Profiles

   5.1. Abbott Laboratories
5.1.1. Snapshot
5.1.2. Overview
5.1.3. Offerings
5.1.4. Financial Insight
5.1.5. Recent Developments
   5.2. Becton Dickinson and Company
5.2.1. Snapshot
5.2.2. Overview
5.2.3. Offerings
5.2.4. Financial Insight
5.2.5. Recent Developments
   5.3. Bio-Rad Laboratories
5.3.1. Snapshot
5.3.2. Overview
5.3.3. Offerings
5.3.4. Financial Insight
5.3.5. Recent Developments
   5.4. Inc.
5.4.1. Snapshot
5.4.2. Overview
5.4.3. Offerings
5.4.4. Financial Insight
5.4.5. Recent Developments
   5.5. Danaher Corporation
5.5.1. Snapshot
5.5.2. Overview
5.5.3. Offerings
5.5.4. Financial Insight
5.5.5. Recent Developments
   5.6. F. Hoffmann-La Roche Ltd.
5.6.1. Snapshot
5.6.2. Overview
5.6.3. Offerings
5.6.4. Financial Insight
5.6.5. Recent Developments
   5.7. Laboratory Corporation of America Holdings (Labcorp)
5.7.1. Snapshot
5.7.2. Overview
5.7.3. Offerings
5.7.4. Financial Insight
5.7.5. Recent Developments
   5.8. Quest Diagnostics Incorporated
5.8.1. Snapshot
5.8.2. Overview
5.8.3. Offerings
5.8.4. Financial Insight
5.8.5. Recent Developments
   5.9. Siemens Healthineers AG
5.9.1. Snapshot
5.9.2. Overview
5.9.3. Offerings
5.9.4. Financial Insight
5.9.5. Recent Developments
   5.10. Thermo Fisher Scientific Inc.
5.10.1. Snapshot
5.10.2. Overview
5.10.3. Offerings
5.10.4. Financial Insight
5.10.5. Recent Developments
   5.11. Trividia Health Inc.
5.11.1. Snapshot
5.11.2. Overview
5.11.3. Offerings
5.11.4. Financial Insight
5.11.5. Recent Developments

6. Appendix

6.1. Exchange Rates
6.2. Abbreviations

Note: Financial insight and recent developments of different companies are subject to the availability of information in the secondary domain.

Vynz Research know in your business needs, you required specific answers pertaining to the market, Hence, our experts and analyst can provide you the customized research support on your specific needs.

After the purchase of current report, you can claim certain degree of free customization within the scope of the research.

Please let us know, how we can serve you better with your specific requirements to your research needs. Vynz research promises for quick reversal for your current business requirements.

U.S. Drug of Abuse (DoA) Testing Market Size & Share - Growth Forecast Report (2026-2035)